Premium
The Effect of Herbal Medicine Baicalin on Pharmacokinetics of Rosuvastatin, Substrate of Organic Anion‐transporting Polypeptide 1B1
Author(s) -
Fan L,
Zhang W,
Guo D,
Tan ZR,
Xu P,
Li Q,
Liu YZ,
Zhang L,
He TY,
Hu DL,
Wang D,
Zhou HH
Publication year - 2008
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/sj.clpt.6100318
Subject(s) - baicalin , rosuvastatin , pharmacokinetics , crossover study , pharmacology , rosuvastatin calcium , organic anion transporting polypeptide , chemistry , placebo , medicine , chromatography , high performance liquid chromatography , biochemistry , alternative medicine , pathology , transporter , gene
The aim of this study was to explore potential herb–drug interaction between baicalin and rosuvastatin, a typical substrate for organic anion‐transporting polypeptide 1B1 (OATP1B1) related to different OATP1B1 haplotype groups. Eighteen unrelated healthy volunteers who were CYP2C9 * 1/*1 with different OATP1B1 haplotypes (six OATP1B1*1b/*1b , six OATP1B1 * 1b/*15 , and six OATP1B1*15/*15 ) were selected to participate in this study. Rosuvastatin (20 mg orally) pharmacokinetics after coadministration of placebo and 50‐mg baicalin tablets (three times daily orally for 14 days) were measured for up to 72 h by liquid chromatography–mass spectrometry in a two‐phase randomized crossover study. After baicalin treatment, the area under the plasma concentration–time curve (AUC) (0–72) and AUC (0–∞) of rosuvastatin decreased by 47.0±11.0% ( P =0.001) and 41.9±7.19% ( P =0.001) in OATP1B1*1b/*1b , 21.0±20.6% ( P =0.035) and 23.9±8.66% ( P =0.004) in OATP1B1*1b/*15 , and 9.20±11.6% ( P =0.077) and 1.76±4.89% ( P =0.36) in OATP1B1*15/*15 , respectively. Moreover, decreases of both AUC (0–72) and AUC (0–∞) of rosuvastatin among different haplotype groups were significantly different ( P =0.002 and <0.001). Baicalin reduces plasma concentrations of rosuvastatin in an OATP1B1 haplotype–dependent manner. Clinical Pharmacology & Therapeutics (2008) 83 , 3, 471–476.doi: 10.1038/sj.clpt.6100318